Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026)
Bausch Health Companies (BHC) posted Income from Non-Controlling Interests of $2.0 million for Q2 2026, up 125.0% sequentially from -$8.0 million in Q1 2026, and up 110.0% YoY from $952381.0 in Q2 2025.
Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Bausch Health Companies has reported Income from Non-Controlling Interests for 14 years, with the latest figure at $2.0 million in Q2 2026.
- Quarterly Income from Non-Controlling Interests rose 110.0% year-over-year to $2.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.0 million (up 110.0% YoY) and the FY2025 annual result came in at -$37.0 million, down 42.31% from the prior year.
- Income from Non-Controlling Interests rose to $2.0 million in Q2 2026 per BHC's latest filing, from -$8.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $9.0 million in Q4 2025 and troughed at -$28.0 million in Q1 2025.
- A 5-year average of -$4.4 million and a median of -$4.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2024: Income from Non-Controlling Interests jumped 200.0% in 2022, then slumped 1200.0% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at $4.0 million in 2022, then slumped by 300.0% to -$8.0 million in 2023, then jumped by 162.5% to $5.0 million in 2024, then soared by 80.0% to $9.0 million in 2025, then tumbled by 77.78% to $2.0 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $2.0 million, -$8.0 million, and $9.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Bausch Health Companies | 2.56 Bn | 725.13 Mn | 2.10 Bn | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -20.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -13.00 Mn |
| Dec 31, 2023 | -8.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 2.00 Mn |